

Status: Currently Official on 16-Feb-2025
Official Date: Official as of 01-Aug-2017
Document Type: USP Monographs
DocId: GUID-70592DA8-D767-4817-B58E-6E762B3CF9FF_1_en-US
DOI: https://doi.org/10.31003/USPNF_M56220_01_01
DOI Ref: z3g89

© 2025 USPC
Do not distribute

Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Acetate Ophthalmic Ointment

DEFINITION

Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Acetate Ophthalmic Ointment is a sterile ointment containing Neomycin Sulfate, Polymyxin B Sulfate, Bacitracin Zinc, and Hydrocortisone Acetate. It contains the equivalent of NLT 90.0% and NMT 140.0% of the labeled amounts of neomycin, polymyxin B, and bacitracin, and NLT 90.0% and NMT 110.0% of the labeled amount of hydrocortisone acetate ($C_{23}H_{32}O_6$).

IDENTIFICATION

- **A. [THIN-LAYER CHROMATOGRAPHIC IDENTIFICATION TEST \(201BNP\)](#):** Meets the requirements
- **B.** The retention time of the hydrocortisone acetate peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay for *Hydrocortisone Acetate*.

ASSAY

• NEOMYCIN

(See [Antibiotics—Microbial Assays \(81\)](#).)

Sample solution: Shake a portion of Ophthalmic Ointment in a separator with 50 mL of [ether](#). Extract with four 20-mL portions of *Buffer B.3*. Combine the aqueous extracts, and dilute with *Buffer B.3* to a suitable volume.

Analysis: Proceed as directed in the chapter. Dilute the *Sample solution* with *Buffer B.3* to obtain a *Test Dilution* having a neomycin concentration that is nominally equivalent to the median level of the standard.

Acceptance criteria: 90.0%–140.0%

• POLYMYXIN B

(See [Antibiotics—Microbial Assays \(81\)](#).)

Sample solution: Shake a portion of Ophthalmic Ointment with 50 mL of [ether](#) in a separator. Extract with four 25-mL portions of *Buffer B.6*. Combine the aqueous extracts, and dilute with *Buffer B.6* to a suitable volume.

Analysis: Proceed as directed in the chapter. Dilute the *Sample solution* with *Buffer B.6* to obtain a *Test Dilution* having a concentration that is nominally equivalent to the median level of the standard (10 polymyxin B Units/mL). Add to each *Test Dilution* of the standard a quantity of [USP Neomycin Sulfate RS](#), dissolved in *Buffer B.6*, to obtain the same concentration of neomycin as in the *Test Dilution* of the sample.

Acceptance criteria: 90.0%–140.0%

• BACITRACIN

(See [Antibiotics—Microbial Assays \(81\)](#).)

Sample solution: Shake a portion of Ophthalmic Ointment with 50 mL of [ether](#) in a separator. Extract with four 25-mL portions of [0.01 N hydrochloric acid](#). Combine the acid extracts, and dilute with [0.01 N hydrochloric acid](#) to a suitable volume.

Analysis: Proceed as directed in the chapter. Dilute the *Sample solution* with *Buffer B.1* to obtain a *Test Dilution* having a concentration that is nominally equivalent to the median level of the standard (1.0 bacitracin Unit/mL). If the *Sample solution* has a concentration of less than 100 bacitracin Units/mL, add hydrochloric acid to each *Test Dilution* of the standard to obtain the same concentration of hydrochloric acid as in the *Test Dilution* of the sample.

Acceptance criteria: 90.0%–140.0%

• HYDROCORTISONE ACETATE

Mobile phase: [Butyl chloride](#), water-saturated [butyl chloride](#), [tetrahydrofuran](#), [methanol](#), and [glacial acetic acid](#) (475:475:70:35:30)

Standard solution: 0.10 mg/mL of [USP Hydrocortisone Acetate RS](#) in water-saturated [chloroform](#)

Sample solution: Nominally 0.10 mg/mL of hydrocortisone acetate from Ophthalmic Ointment prepared as follows. Transfer a portion of Ophthalmic Ointment containing nominally 2.5 mg of hydrocortisone acetate to a closable container. Add 25.0 mL of water-saturated [chloroform](#) and about 10 glass beads. Securely close the container, and shake vigorously for approximately 15 min. Centrifuge, and use the clear, lower chloroform layer.

Chromatographic system
(See [Chromatography \(621\)](#), [System Suitability](#).)
Mode: LC
Detector: UV 254 nm
Column: 3.9-mm × 30-cm; 10-µm packing [L3](#)
System suitability
Sample: *Standard solution*
Suitability requirements
Relative standard deviation: NMT 2.0%

Analysis
Samples: *Standard solution* and *Sample solution*
Calculate the percentage of the labeled amount of hydrocortisone acetate (C₂₃H₃₂O₆) in the portion of Ophthalmic Ointment taken:

Result = $(r_U/r_S) \times (C_S/C_U) \times 100$

- r_U = peak response from the *Sample solution*
 r_S = peak response from the *Standard solution*
 C_S = concentration of [USP Hydrocortisone Acetate RS](#) in the *Standard solution* (mg/mL)
 C_U = nominal concentration of hydrocortisone acetate in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

- SPECIFIC TESTS**
• **STERILITY TESTS (71):** Meets the requirements
• **OTHER REQUIREMENTS:** It meets the requirements for *Particulate and Foreign Matter* and *Container Contents* in [Ophthalmic Products—Quality Tests \(771\)](#), [Drug Product Quality, Universal Tests, Particulate and Foreign Matter](#) and [Container Contents](#).

- ADDITIONAL REQUIREMENTS**
• **PACKAGING AND STORAGE:** Preserve in collapsible ophthalmic ointment tubes. Store at controlled room temperature.
• **USP REFERENCE STANDARDS (11).**
[USP Bacitracin Zinc RS](#)
[USP Hydrocortisone Acetate RS](#)
[USP Neomycin Sulfate RS](#)
[USP Polymyxin B Sulfate RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC, AND HYDROCORTISONE ACETATE OPHTHALMIC OINTMENT	Julie Zhang Associate Science & Standards Liaison	BIO42020 Biologics Monographs 4 - Antibiotics
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	BIO42020 Biologics Monographs 4 - Antibiotics

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. PF 39(5)

Current DocID: GUID-70592DA8-D767-4817-B58E-6E762B3CF9FF_1_en-US
DOI: https://doi.org/10.31003/USPNF_M56220_01_01
DOI ref: [z3g89](#)